Boltz raises $110M Series A to sell drug design by the token
Bessemer leads Boltz's $110M Series A. The London AI lab sells molecular design by the token, usage is up roughly 50-fold in four months, and the market compounds near 30%.
Also see more funding coverage: /funding/
London, United Kingdom
London-based Boltz raised a $110M Series A led by Bessemer Venture Partners, with Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures returning, to put more research, compute and data behind its biomolecular foundation models.
The lead check for this London round came from a US firm, and that is the hard fact. The good news is that the company, its researchers and its product sit in King’s Cross. Below, I lay out what the round contains, what Boltz sells, how fast its market is growing and what the cap table tells us about London’s place in AI-driven biotech.
Get the Weekly brief
The week’s rounds, last calls and events, every Monday.
A $110M Series A with Bessemer in the lead
Bessemer Venture Partners announced on November 18 that it is leading Boltz’s $110M Series A, and Andreessen Horowitz published its own note the same day. Tech.eu reports that Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures are existing investors taking part again, and that Greycroft, F-Prime Capital, Hummingbird and Benchling are new. The round follows a $28M seed at the start of 2026, per tech.eu.
On use of funds, Andreessen Horowitz writes that “the opportunity now is to invest more deeply in research, compute, and data.” Boltz makes the same point in its statement to tech.eu: “Reaching that goal will require further advances in the models and substantial investment in compute and data.”
Forty researchers and a meter that counts molecular tokens
Boltz spun out of Professor Regina Barzilay’s lab at MIT. Its three co-founders are Gabriele Corso, Jeremy Wohlwend and Saro Passaro, and tech.eu counts about 40 AI researchers on the team, based in King’s Cross. The company emerged from stealth less than a year ago, according to tech.eu.
It builds foundation models for biomolecular modeling and for small-molecule and protein design. Boltz-1 and Boltz-2 cover structure and affinity prediction, BoltzGen covers generative protein design, and BoltzMol-1 and BoltzProt-1 cover the two design tasks. Scientists reach them through a web interface, an API and agent integrations, and Boltz prices usage in “molecular tokens.”
The traction figures come from the investors’ own posts, so read them as claims. Bessemer and Andreessen Horowitz report more than 100,000 scientists using the models, over 5 million open-source downloads, a roughly 50-fold rise in weekly molecular-token consumption in four months, and deployments at Pfizer, GSK, Takeda and Bristol Myers Squibb.
A market compounding at 30 percent a year
BCC Research projects AI in pharmaceuticals to grow from $3.8 billion in 2025 to $15.2 billion by 2030, a 31.7% CAGR (report published November 17, 2025). For the narrower segment of AI in drug discovery, MarketsandMarkets puts the market at $1.86 billion in 2024 and $6.89 billion by 2029, a 29.9% CAGR (published November 2024). The two firms draw the segment differently, and both forecasts predate Boltz’s usage numbers.
Set against those figures, the reality is stark. By our arithmetic, one $110M Series A equals about 3% of BCC’s 2025 market estimate. The silver lining sits in the same numbers. If a market compounds at close to 30% a year, a company whose token consumption grew roughly 50-fold in four months is growing far faster than the market around it.
Our own desk gives the scale. Boltz’s round is more than three times the size of the $34M Series A Orakl Oncology raised on November 13, and it closed the same week as Isomorphic Labs’ $5bn Series C.
What the cap table says about London
The lead investor, Bessemer, and the largest returning backers, Andreessen Horowitz, Amplify and Zetta, are US firms. Hummingbird, Greycroft, F-Prime and Benchling joined the table for this round. London supplies the team and the product, and capital for the compute bill still arrives mostly from across the Atlantic.
We are watching three things. Whether usage keeps compounding at the pace the investors report, whether the next compute-heavy round in this segment has a European lead, and how fast the open-source models turn into paid molecular tokens. Every one of these rounds lands in our European fundraising data.
Imagine if the next lead check for a London lab like this one were written by a European fund. The talent already ships from King’s Cross. Let’s give it a home-grown first call on the capital!